Contact: Pamela Larkin, 408-466-5952, email@example.com
Washington, DC (October 29, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding C2N Diagnostics’ release of the PrecivityADTM blood test.
“Congratulations to the C2N Diagnostics team for successfully developing the first blood test of its kind for Alzheimer’s disease. It will transform how doctors treat patients and greatly accelerate the discovery of therapies and cures.
Having an accurate and fast blood test to indicate Alzheimer’s pathology will streamline the referral and screening process for clinical trials. It’s also a breakthrough for physicians, who will obtain a better indication of whether patients with cognitive issues have Alzheimer’s pathology in the brain without costly scans or invasive procedures.
It’s important that this technology be available to everyone who wonders if they have Alzheimer’s. Government and private payers should move quickly to fairly reimburse for this, and any other Alzheimer’s tests shown to be clinically effective.”
About the Global Alzheimer’s Platform Foundation (GAP)
The Global Alzheimer’s Platform Foundation® (GAP) is a patient-centric nonprofit dedicated to accelerating the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials. Research centers across the US and Canada are part of the growing GAP Network (GAP-Net). GAP supports GAP-Net research centers by assisting with study start up and recruitment activities, promoting diversity in research studies, and offering national programs that champion brain health and the citizen scientists who make research possible.